Abstract PD13-01: PD13-01 Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trialMaría Vidal, Meritxell Bellet Ezquerra, Tomás Pascual et al.|Cancer Research|2023Cited by 12
Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Clinical Cancer Research|2025Cited by 7
Abstract OT2-11-07: Solti-1905. Elacestrant in preoperative setting, a window of opportunity study (ELIPSE trial)María Vidal, Meritxell Bellet, Montserrat Muñoz-Mateu et al.|Cancer Research|2022Cited by 4
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast CancerEsther Sanfeliu, Aleix Prat, Blanca González‐Farré et al.|Clinical Cancer Research|2025Cited by 3
Supplementary Figure S3 from Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE TrialMaría Vidal, Meritxell Bellet, Claudette Falato et al.|Unknown|2025Cited by 0